Patents Assigned to Assistance Publique
-
Publication number: 20240131138Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.Type: ApplicationFiled: December 22, 2021Publication date: April 25, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
-
Publication number: 20240131505Abstract: A magnetic locking device for a pipetting tool, the device having a plate that is able to be adapted to the pipetting tool, an accessory being intended to be fastened to a fastening end piece that is supported by the plate and/or intended to be supported by the pipetting tool. The device has at least one lock configured to switch from an active state to a passive state, and vice versa, such that, in the active state, the lock is able to block, in service, particles that are present in the accessory, and such that, in the passive state of the lock, the particles are free to move in the accessory.Type: ApplicationFiled: February 25, 2022Publication date: April 25, 2024Applicants: UNIVERSITE DE VERSAILLES-SAINT-QUENTIN-EN-YVELINES, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - I.N.S.E.R.M.Inventor: Martin ROTTMAN
-
Publication number: 20240130358Abstract: An organ perfusion and preservation system for use in preserving an organ from a donor, may include a fluid reservoir, a heat exchanger in fluid communication with the fluid reservoir and configured to selectively raise and lower a temperature of a perfusion fluid, an oxygenator configured to oxygenate the perfusion fluid, an inflow pump in fluid communication with the fluid reservoir and the oxygenator, a fluid inflow line configured to transport perfusion fluid from the oxygenator to the organ, a fluid outflow line configured to transport perfusion fluid away from the organ and back to the reservoir, an outflow pump in fluid communication with the fluid outflow line and the fluid reservoir, and a controller operatively connected to the inflow pump, the outflow pump, and the heat exchanger, wherein the controller is configured to select parameters to reversibly heat and reversibly cool the organ.Type: ApplicationFiled: January 3, 2024Publication date: April 25, 2024Applicants: SORIN GROUP ITALIA S.R.L., SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE- HOPITAUX DE PARISInventors: John F. Migliazza, Sandra Spiritelli, Olivier Scatton, Eric Savier, Claire Goumard
-
Patent number: 11965894Abstract: The present invention relates to new methods for assessing prognosis of recovery of DILI in a patient, combining measurement of serum markers through a logistic function that doesn't include bilirubin and transaminases (AST and ALT) markers.Type: GrantFiled: March 6, 2018Date of Patent: April 23, 2024Assignees: BIOPREDICTIVE, ASSISTANCE PUBLIQUE -HOPITAUX DE PARISInventor: Thierry Poynard
-
Publication number: 20240124532Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.Type: ApplicationFiled: January 28, 2022Publication date: April 18, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val De Marne, Baylor Research InstituteInventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI, Mireille CENTLIVRE, Lydie DIEUDONNE, Sylvain CARDINAUD
-
Publication number: 20240115371Abstract: A vascular prosthesis may be implanted in a vessel, having substantially a T-shape, that includes a proximal tubular part forming the base of the “T” and a distal tubular part forming the head of the “T”. The second end portion of the distal tubular part is formed by a flap. The flap is opposed to a circumferential indentation in the deployed position. The structural frame of the flap includes an arched segment connected at its ends to the intermediate portion of the distal tubular part. The arched segment is bendable so as to form a joint for the folding/unfolding movement of the flap.Type: ApplicationFiled: April 6, 2022Publication date: April 11, 2024Applicants: UNIVERSITÉ D'AIX MARSEILLE, ASSISTANCE PUBLIQUE-HÔPITAUX DE MARSEILLE, Université Gustave Eiffel, Bypass SolutionsInventors: Yves Simon Alimi, Frédéric Mouret, Vincent Garitey, David Baas
-
Patent number: 11951090Abstract: FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (?)-epicatechin from T. cacao and showed that (?)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (?)-epicatechin for the treatment of FGFR3-related chondrodysplasias.Type: GrantFiled: January 23, 2019Date of Patent: April 9, 2024Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE PARIS, FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS, UNIVERSIDAD DE GRANADAInventors: Laurence Legeai-Mallet, Antonio Segura Carretero, Maria De La Luz Cadiz Gurrea
-
Patent number: 11946909Abstract: The present invention relates to an asymmetric flow field-flow fractionation device (1) configured to separate a sample (8) of particles (12) dispersed in a liquid mobile phase (11), the device including a fractionation microchannel (2) comprising a sample inlet, a sample outlet, an auxiliary microchannel (3) comprising an auxiliary outlet, a semipermeable membrane (10) separating the fractionation microchannel (2) and the auxiliary microchannel (3), said membrane being permeable to liquid and being configured to maintain the particles (12) in said fractionation microchannel (2), the fractionation microchannel (2) being superimposed on the auxiliary microchannel (3), wherein the device (1) comprises two layers (19), each layer being with a microfabricated recess (14) which thickness (t) is less than 100IJm, the membrane (10) being mechanically held in between the two layers (19), the recesses (14) respectively defining the fractionation microchannel (2) and the auxiliary microchannel (3) on each side of the mType: GrantFiled: February 21, 2019Date of Patent: April 2, 2024Assignees: Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS), Institut National de le Recherche Scientifique (CNRS), UNIVERSITÉ PARIS CITÉ, Ecole Nationale Superieure de Chimie de ParisInventors: Hugo Salmon, Rabah Gahoual, Nathalie Mignet, Pascal Houze
-
Patent number: 11905330Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.Type: GrantFiled: September 26, 2022Date of Patent: February 20, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS CITÉ, SORBONNE UNIVERSITÉInventors: Guido Kroemer, José Manuel Bravo San Pedro
-
Patent number: 11903382Abstract: Disclosed is a device for the perfusion of an organ, including: a container of fluid, containing an organ bathed in the perfusion fluid; a first path including an inlet, an outlet and a pump; and a second path including an inlet, an outlet and a pump. The “arterial” outlet of the first path has a diameter smaller than a diameter of the “portal” outlet of the second path. The device additionally includes, between the pump and the outlet of the first path and/or between the pump and the outlet of the second path, an oxygenation unit arranged to oxygenate the fluid emerging from the “arterial” outlet of the first path more than the fluid emerging from the “portal” outlet of the second path. The device can include a communication path between the first path and the second path in order to oxygenate the second path. Use in liver transplantation.Type: GrantFiled: January 11, 2023Date of Patent: February 20, 2024Assignees: UNIVERSITE DE TECHNOLOGIE DE COMPIEGNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SORBONNE UNIVERSITE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARISInventors: Cécile Legallais, Patrick Paullier, Olivier Scatton, Eric Savier
-
Publication number: 20240050390Abstract: The present invention relates to an embolizing emulsion comprising iodinated oil and an aqueous phase comprising a water-soluble contrast agent for use in the treatment of inflammatory hypervascularization associated with a musculoskeletal disorder.Type: ApplicationFiled: December 10, 2021Publication date: February 15, 2024Applicants: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, GUERBET, UNIVERSITÉ PARIS CITÉInventors: Marc SAPOVAL, Constantino DEL GIUDICE, Carole DEAN, Olivier PELLERIN
-
Publication number: 20240033366Abstract: Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.Type: ApplicationFiled: December 2, 2021Publication date: February 1, 2024Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT À L’ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), UNIVERSITE PARIS CITE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS)Inventors: Ludger JOHANNES, Anne BILLET, Jonathan ULMER, Denis SERVENT, Gilles MOURIER, Pascal KESSLER, Eric TARTOUR
-
Patent number: 11872413Abstract: The present invention relates to a method for controlling a probe for the treatment of brain tissue using an assembly comprising the probe and an acoustic window (1), the probe (2) including a plurality of transducers (21) for generating ultrasound waves, the method comprising: —a phase of detection: •of the probe transducers situated above the cranium (4) of the patient, and •of the probe transducers situated above the acoustic window (1), so as to permit: •deactivation of the transducers situated above the cranium (4) of the patient, •activation of the transducers situated above the acoustic window (1).Type: GrantFiled: June 19, 2018Date of Patent: January 16, 2024Assignees: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITE, CARTHERAInventors: Alexandre Carpentier, Guillaume Bouchoux, Michael Canney, Francois Lacoste
-
Publication number: 20240010739Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.Type: ApplicationFiled: November 10, 2021Publication date: January 11, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT
-
Patent number: 11857532Abstract: Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia.Type: GrantFiled: December 27, 2019Date of Patent: January 2, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)Inventors: Anne Agnès Rotig, Arnold Munnich, Floriane Petit
-
Patent number: 11849958Abstract: The present invention relates to a surgical kit for use in a craniectomy procedure, the surgical kit comprising: a medical device to be implanted in a cranial bone of a patient, the medical device (10) including several transducers for emitting ultrasound waves for treatment of brain tissue, a surgical accessory (20) intended to be positioned on the cranial bone of the patient, the surgical accessory (20) including a body whose outer perimeter defines the dimensions of an opening that is to be made in the cranial bone of the patient in order to receive the medical device, characterized in that the surgical accessory (20) comprises a plurality of holes (201) formed in the body, the position of each hole (201) on the body coinciding with the position of the axis of symmetry of a respective transducer, such that the accessory is able to be positioned optimally through the joint use of a neuronavigation system.Type: GrantFiled: March 13, 2019Date of Patent: December 26, 2023Assignees: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITE, CARTHERAInventors: Alexandre Carpentier, Alexandre Vignot, Matthieu Cholvy
-
Publication number: 20230372078Abstract: A percutaneous bypass method for implanting a bypass graft between two vessels is described. The bypass graft comprises a first part and a second part, each having a tubular shape and comprising respective lumens. The method comprises the step of inserting a second sheath, from the outside to the inside of a bypass portion of the first part, through a puncture therein, and retracting the second sheath so as to deploy and implant a hook portion of the second part into the second vessel, and deploy a bypass portion of the second part outside the second vessel, from the second vessel to the first part, and within the lumen of the first part.Type: ApplicationFiled: October 6, 2020Publication date: November 23, 2023Applicants: UNIVERSITÉ D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE - HÔPITAUX DE MARSEILLE, Université Gustave EiffelInventor: Yves Alimi
-
Publication number: 20230365936Abstract: The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesicles, and fractions thereof. The present disclosure further provides methods for analyzing activities, and the functionality and potency, of such secretomes, extracellular vesicles, and fractions thereof. The present disclosure also relates to the therapeutic use of secretomes, extracellular vesicles, and fractions thereof. The present disclosure further relates to a good manufacturing practices (GMP)-ready, scalable, culture protocol for the release of clinic-ready secretomes.Type: ApplicationFiled: May 17, 2023Publication date: November 16, 2023Applicants: FUJIFILM Corporation, Assistance Publique - Hôpitaux de ParisInventors: Nisa K. E. RENAULT, Michele L. Hamrick, Chad H. Koonce, Philippe Menasche, Valerie Bellamy, Camille Humbert, Guillaume Churlaud, Jerome Larghero
-
Publication number: 20230321059Abstract: The present invention relates to a compound selected from mepyramine, prodrugs thereof and pharmaceutically acceptable salts thereof, or a composition comprising such a compound, for use in the topical treatment and prevention of neuropathic pain.Type: ApplicationFiled: September 10, 2021Publication date: October 12, 2023Applicants: Assistance Publique - Hopitaux de Paris, Centre National de la Recherche ScientifiqueInventors: Céline Greco, Patrick Delmas
-
Publication number: 20230293586Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.Type: ApplicationFiled: April 6, 2023Publication date: September 21, 2023Applicants: Assistance Publique - Hopitaux de Paris, Fondation Imagine - Institut des Maladies Génétiques, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Isabelle ANDRÉ, Marina CAVAZZANA, Kuiying MA, John TCHEN, Tayebeh-Shabi SOHEILI, Ranjita Devi MOIRANGTHEM